Neil Warma - Opexa Therapeutics CEO and President and Director
CEO
Mr. Neil K. Warma is President, Chief Executive Officer, Acting Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, Director of the Comapany. He has served as President and Chief Executive Officer since June 2008 and as a Director since September 2008. He also previously served as our Acting Chief Financial Officer from March 2009 to August 2012. From July 2004 to September 2007, Mr. Warma served as president and chief executive officer of Viron Therapeutics Inc., a privatelyheld clinical stage biopharmaceutical company. From 2000 to 2003 Mr. Warma was cofounder and president of MedExact USA, Inc., an Internet company providing clinical information and services to physicians and pharmaceutical companies. From 1992 to 2000, Mr. Warma held senior positions of increasing responsibility at Novartis Pharmaceuticals at its corporate headquarters in Basel, Switzerland. While at Novartis, Mr. Warma served as the Head of International Pharma Policy Advocacy and in senior management within global marketing where he worked on the international launch of a gastrointestinal product since 2016.
| Age | 52 |
| Tenure | 8 years |
| Professional Marks | MBA |
| Phone | 281-272-9331 |
| Web | http://www.opexatherapeutics.com |
Opexa Therapeutics Management Efficiency
The company has return on total asset (ROA) of (37.76) % which means that it has lost $37.76 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (141.4) %, meaning that it created substantial loss on money invested by shareholders. Opexa Therapeutics' management efficiency ratios could be used to measure how well Opexa Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 26.53 K in liabilities with Debt to Equity (D/E) ratio of 1.6, which is about average as compared to similar companies. Opexa Therapeutics has a current ratio of 5.26, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Opexa Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Opexa Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Opexa Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Opexa to invest in growth at high rates of return. When we think about Opexa Therapeutics' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Found 9 records | CEO Age | ||
| Maxime Seche | Seche Environnement SA | 34 | |
| Martin Riant | Procter Gamble | 55 | |
| Shailesh Jejurikar | Procter Gamble | 57 | |
| Richard Marabito | Olympic Steel | 60 | |
| Richard ODell | Saia Inc | 56 | |
| Fama Francisco | Procter Gamble | 50 | |
| Ma Francisco | Procter Gamble | 52 | |
| Donald McNeeley | Olympic Steel | 70 | |
| Frederick III | Saia Inc | 56 | |
Management Performance
| Return On Equity | -141.4 | |||
| Return On Asset | -37.76 |
Opexa Therapeutics Leadership Team
Elected by the shareholders, the Opexa Therapeutics' board of directors comprises two types of representatives: Opexa Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Opexa. The board's role is to monitor Opexa Therapeutics' management team and ensure that shareholders' interests are well served. Opexa Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Opexa Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Gail Maderis, Independent Director | ||
| Timothy Barabe, Director | ||
| Michael Richman, Independent Director | ||
| Neil Warma, CEO and President and Director | ||
| Don Healey, Chief Scientific Officer | ||
| HansPeter Hartung, Director | ||
| Karthik Radhakrishnan, CFO | ||
| Donna Rill, Chief Development Officer | ||
| Scott Seaman, Independent Director |
Opexa Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Opexa Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -141.4 | |||
| Return On Asset | -37.76 | |||
| Profit Margin | (232.31) % | |||
| Operating Margin | (150.62) % | |||
| Current Valuation | 6.01 M | |||
| Shares Outstanding | 7.66 M | |||
| Shares Owned By Insiders | 1.25 % | |||
| Shares Owned By Institutions | 3.30 % | |||
| Number Of Shares Shorted | 541.25 K | |||
| Price To Earning | (1.34) X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in interest. You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Other Consideration for investing in Opexa Stock
If you are still planning to invest in Opexa Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Opexa Therapeutics' history and understand the potential risks before investing.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon |